Media Advisory - Bioniche Discusses USDA Comment on E. Coli O157:H7 Cattle Vaccine Field Trial
Posted on: Friday, 5 October 2007, 18:00 CDT
BELLEVILLE, ON, Oct. 5 /PRNewswire-FirstCall/ -- Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company (TSX:BNC), will be discussing the U.S. Department of Agriculture (USDA) comment on a field trial for its E. coli O157:H7 cattle vaccine during a:
Conference Call & Audio Web Cast Tuesday, October 9, 2007 9:00 a.m. (Eastern)
To participate in the teleconference, call 416-644-3414/toll-free 1-800-733-7571.
A listen-only audio web cast will be available at: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2039180 (English) http://www.cnw.ca/fr/webcast/viewEvent.cgi?eventID=2039180 (French)
A replay of the conference call will be available until October 16, 2007 by calling (416) 640-1917 or toll-free 1-877-289-8525 (passcode: 21249516 followed by the number sign).
The web cast will be available for replay using the above links until January 9, 2008.
About Bioniche Life Sciences
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 195 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. For more information, please visit http://www.bioniche.com/.
Bioniche Life Sciences Inc.
CONTACT: Jennifer Shea, Corporate Communications & Investor RelationsManager, Bioniche Life Sciences Inc., P.O. Box 1570, Belleville, ON, K8N 5J2,Telephone: (613) 966-8058 ext. 1250, Cell: (613) 391-2097,Jennifer.Shea@Bioniche.com
Source: PRNewswire-FirstCall
Related Articles
- DBMS Consulting Receives Honorable Mention in Life Sciences & Health Care Industry Solution Category at "Oracle Open World 2009 North America Alliances & Channels Titan Award Ceremony"
- Life Sciences & Health Care Companies Unprepared for Information Security Risks: Deloitte Survey
- Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
- Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research
- Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
- Advanced Life Sciences Announces Fourth Quarter and Full Year 2006 Results
- Bioniche Life Sciences Experiences Significant Trading Volume Following Progress Update on E. Coli O157:H7 Cattle Vaccine Canadian Regulatory Status
- Bioniche Life Sciences Clears Path for Priority Review of Its E. Coli O157:H7 Cattle Vaccine in Canada
- Advanced Life Sciences Announces Third Quarter 2006 Results
- BioCrossroads, Other Partners Secure Foundation Gifts Totaling $10.5 M to Form Indiana Life Sciences Entity Focused on Improving Human Health
 |
 |
User Comments (0)
RSS Feeds